Drugs / bbT369
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05169489 | Jan 2022 → Sep 2025 | diffuse large B-cell lymphoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bbT369 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05169489 ↗ |
| Modality | Cell therapy | “genetically modified autologous T cell immunotherapy product” NCT05169489 ↗ |
| Target | CBLB | “the CBLB-targeting megaTAL enzyme to edit the CBLB gene” NCT05169489 ↗ |